JP4969065B2 - 常温性イオン性液体を含有する医薬組成物 - Google Patents
常温性イオン性液体を含有する医薬組成物 Download PDFInfo
- Publication number
- JP4969065B2 JP4969065B2 JP2005204553A JP2005204553A JP4969065B2 JP 4969065 B2 JP4969065 B2 JP 4969065B2 JP 2005204553 A JP2005204553 A JP 2005204553A JP 2005204553 A JP2005204553 A JP 2005204553A JP 4969065 B2 JP4969065 B2 JP 4969065B2
- Authority
- JP
- Japan
- Prior art keywords
- ionic liquid
- room temperature
- pharmaceutical composition
- composition containing
- temperature ionic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000011829 room temperature ionic liquid solvent Substances 0.000 title description 6
- 239000008194 pharmaceutical composition Substances 0.000 title description 3
- 239000002608 ionic liquid Substances 0.000 claims description 18
- 229940088679 drug related substance Drugs 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 7
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 claims description 5
- 229930012538 Paclitaxel Natural products 0.000 claims description 5
- 229960001592 paclitaxel Drugs 0.000 claims description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 5
- 238000011978 dissolution method Methods 0.000 claims description 3
- AFSJUFFXOPXIOH-UHFFFAOYSA-N 1-ethyl-3-methyl-1,2-dihydroimidazol-1-ium;trifluoromethanesulfonate Chemical compound CC[NH+]1CN(C)C=C1.[O-]S(=O)(=O)C(F)(F)F AFSJUFFXOPXIOH-UHFFFAOYSA-N 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 125000002456 taxol group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 229940079593 drug Drugs 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 150000001450 anions Chemical class 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- OIWSIWZBQPTDKI-UHFFFAOYSA-N 1-butyl-3-methyl-2h-imidazole;hydrobromide Chemical compound [Br-].CCCC[NH+]1CN(C)C=C1 OIWSIWZBQPTDKI-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005204553A JP4969065B2 (ja) | 2005-07-13 | 2005-07-13 | 常温性イオン性液体を含有する医薬組成物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005204553A JP4969065B2 (ja) | 2005-07-13 | 2005-07-13 | 常温性イオン性液体を含有する医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007022942A JP2007022942A (ja) | 2007-02-01 |
| JP2007022942A5 JP2007022942A5 (enExample) | 2008-08-28 |
| JP4969065B2 true JP4969065B2 (ja) | 2012-07-04 |
Family
ID=37784185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005204553A Expired - Fee Related JP4969065B2 (ja) | 2005-07-13 | 2005-07-13 | 常温性イオン性液体を含有する医薬組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4969065B2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3395368A1 (en) | 2014-10-30 | 2018-10-31 | Asahi Kasei Kabushiki Kaisha | Transdermal absorption enhancer and transdermal absorption enhancement aid |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016002368A (ja) * | 2014-06-18 | 2016-01-12 | 日本電信電話株式会社 | 経皮薬物送達システム |
| BR112019026222A2 (pt) * | 2017-06-16 | 2020-06-30 | Medrx Co., Ltd. | preparação externa, e, processo para preparar a preparação externa |
| CA3157143A1 (en) | 2019-10-11 | 2021-04-15 | Toray Industries, Inc. | Pharmaceutical composition containing temperature-responsive ionic liquid |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4011830B2 (ja) * | 2000-06-20 | 2007-11-21 | 独立行政法人科学技術振興機構 | Ｎ−アルコキシアルキルイミダゾリウム塩、該イミダゾリウム塩からなるイオン液体ならびにイオン性ゲル |
| JP4039828B2 (ja) * | 2001-08-24 | 2008-01-30 | セントラル硝子株式会社 | イオン液体組成物 |
| US6808557B2 (en) * | 2001-10-03 | 2004-10-26 | The University Of Alabama | Cellulose matrix encapsulation and method |
| AU2002950862A0 (en) * | 2002-08-19 | 2002-09-12 | Biosignal Pty Ltd | Furanone derivatives and methods of making same |
| US20050152979A1 (en) * | 2003-09-05 | 2005-07-14 | Cell Therapeutics, Inc. | Hydrophobic drug compositions containing reconstitution enhancer |
-
2005
- 2005-07-13 JP JP2005204553A patent/JP4969065B2/ja not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3395368A1 (en) | 2014-10-30 | 2018-10-31 | Asahi Kasei Kabushiki Kaisha | Transdermal absorption enhancer and transdermal absorption enhancement aid |
| EP3395369A1 (en) | 2014-10-30 | 2018-10-31 | Asahi Kasei Kabushiki Kaisha | Transdermal absorption enhancer and transdermal absorption enhancement aid |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007022942A (ja) | 2007-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR0136722B1 (ko) | 택산류 유도체를 기재로한 신규한 조성물 | |
| JP3689791B2 (ja) | タキソイドに基づく新規な組成物 | |
| HK1006207B (en) | Novel compositions based on taxane class derivatives | |
| AU2002306329B2 (en) | Aqueous cilostazol preparation for injection | |
| JP6836825B2 (ja) | 水不溶性またはわずかに水溶性の薬剤の水可溶性を改善するための方法 | |
| JP2003535893A (ja) | 透明水性麻酔剤組成物 | |
| RS20070461A (sr) | Injektibilne kompozicije i postupak za njihovo dobijanje | |
| CA2494157C (en) | Inclusion complexes of butylphthalide with cyclodextrin or its derivatives, a process for their preparation and the use thereof | |
| JP2007531725A (ja) | 癌治療用の注射可能な組成物 | |
| JP4969065B2 (ja) | 常温性イオン性液体を含有する医薬組成物 | |
| AU2024205837A1 (en) | Formulations of docetaxel | |
| JP2019526572A (ja) | ベンダムスチン溶液製剤 | |
| CA2642324C (en) | Stable pharmaceutical composition of taxanes | |
| JP7577364B2 (ja) | 注射用ドセタキセル組成物およびそのための調製法 | |
| US20170035831A1 (en) | Composition comprising bortezomib | |
| BR112013005763B1 (pt) | Injeção de 5a-androstano-3ss, 5, 6ss-triol e método para prrparação da injeção | |
| JP2010531827A (ja) | 抗腫瘍剤用ビヒクルとしてのシクロデキストリン系ナノスポンジ | |
| JP2010030906A (ja) | 難水溶性薬剤の薬液製剤、その薬液製剤製造方法および希釈薬液製剤製造方法 | |
| JP2013194009A (ja) | ドセタキセル製剤 | |
| KR20200059221A (ko) | 시포니모드를 포함하는 비경구 제형 | |
| JP2023541265A (ja) | カバジタキセル製剤 | |
| CN113365617B (zh) | 用于医学疾病治疗的一氧化碳前药 | |
| JP6292267B2 (ja) | ドセタキセル製剤 | |
| CN100467024C (zh) | 氯诺昔康注射用组合物及其制备方法 | |
| JP2005521712A (ja) | 弱塩基の可溶化 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080710 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080710 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20111020 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111115 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111227 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120214 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120216 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120327 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120403 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150413 Year of fee payment: 3 |
|
| R150 | Certificate of patent (=grant) or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |